2. GPCR/G Protein Cell Cycle/DNA Damage Apoptosis
  3. Formyl Peptide Receptor (FPR) PERK Apoptosis
  4. WKYMVm

WKYMVm is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs. WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

WKYMVm

WKYMVm Chemical Structure

CAS No. : 187986-17-0

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of WKYMVm:

WKYMVm Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

WKYMVm is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs. WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor[1][2][3][4][5][6][7].

IC50 & Target

FPR1, FPRL1[1], FPRL2[2]
Cellular Effect
Cell Line Type Value Description References
HL-60 EC50
0.001 μM
Compound: WKYMVm
Agonist activity at FPRL1 expressed in human HL60 cells assessed as induction of intracellular calcium flux by FLIPR3 calcium assay
Agonist activity at FPRL1 expressed in human HL60 cells assessed as induction of intracellular calcium flux by FLIPR3 calcium assay
[PMID: 19639995]
HL-60 EC50
0.01 μM
Compound: WKYMVm
Agonist activity at FPRL2 expressed in human HL60 cells assessed as induction of intracellular calcium flux by FLIPR3 calcium assay
Agonist activity at FPRL2 expressed in human HL60 cells assessed as induction of intracellular calcium flux by FLIPR3 calcium assay
[PMID: 19639995]
HL-60 EC50
0.5 μM
Compound: WKYMVm
Agonist activity at FPR1 expressed in human HL60 cells assessed as induction of intracellular calcium flux by FLIPR3 calcium assay
Agonist activity at FPR1 expressed in human HL60 cells assessed as induction of intracellular calcium flux by FLIPR3 calcium assay
[PMID: 19639995]
In Vitro

WKYMVm (0-5 μmol/L; 2 h) inhibits the production of inflammatory cytokines (TNF-α, IL-6 and IL-1β) in LPS (HY-D1056) treated microglia [3].
WKYMVm (1-100 µM; 0-24 h) can increase FPR2 mRNA level and ERK phosphorylation level in HUVECs cells, promote HUVECs tube formation and cell proliferation[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

WKYMVm Related Antibodies
In Vivo

WKYMVm (4 mg/kg; Intraperitoneal injection; 3 times; 24 h interval) has a protective effect in rat spinal cord injury model[3].
WKYMVm (2.5 mg/kg; Intraperitoneal injection; 4 days) can alleviate hyperoxy-induced lung injury in neonatal mice[4].
WKYMVm (8 mg/kg; Subcutaneous injection; Once every two days; 2-5 weeks) improves obesity in high-fat fed mouse models[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Adult female Sprague-Dawley rats (200-220 g) with spinal cord injury[3]
Dosage: 4 mg/kg
Administration: Intraperitoneal injection (i.p.); 3 times with 24 hours intervals
Result: Reduce structural disorders and neuronal loss.
Reduced the phosphorylation of ERK1/2 and NF-κB p65 but not p38.
Animal Model: Normoxia or hyperoxic treated newborn mouse pups of C57/BL6[4]
Dosage: 2.5 mg/kg
Administration: Intraperitoneal injection (i.p.); daily from postnatal day (P) 5 to P8.
Result: Significantly attenuated hyperoxia-induced lung inflammation, as evidenced by increased inflammatory cytokines, neutrophils, and alveolar macrophages, and resultant lung injuries, which included impaired alveolarization and angiogenesis, an increased number of apoptotic cells, and reduced levels of growth factors in vivo, such as vascular endothelial growth factor and hepatocyte growth factor.
Animal Model: High fat diet treated male wild-type C57BL/6N mice aged 8 weeks old (21 ± 2 g)[5]
Dosage: 8 mg/kg
Administration: Subcutaneous injection (i.h.); once every 2 days; 2 or 5 weeks
Result: Significantly attenuated body weight gain, food intake and increased insulin sensitivity.
Markedly ameliorated HFD-induced hepatic steatosis and adipose tissue hypertrophy.
Improved lipid metabolism in adipose tissue.
Improved leptin signalling in the hypothalamus.
Molecular Weight

856.11

Formula

C41H61N9O7S2
CAS No.
Appearance

Solid

Color

White to off-white

Sequence

Trp-Lys-Tyr-Met-Val-{d-Met}-NH2
Sequence Shortening

WKYMV-{d-Met}-NH2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture and light

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (116.81 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.1681 mL 5.8404 mL 11.6807 mL
5 mM 0.2336 mL 1.1681 mL 2.3361 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (2.92 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.1681 mL 5.8404 mL 11.6807 mL 29.2019 mL
5 mM 0.2336 mL 1.1681 mL 2.3361 mL 5.8404 mL
10 mM 0.1168 mL 0.5840 mL 1.1681 mL 2.9202 mL
15 mM 0.0779 mL 0.3894 mL 0.7787 mL 1.9468 mL
20 mM 0.0584 mL 0.2920 mL 0.5840 mL 1.4601 mL
25 mM 0.0467 mL 0.2336 mL 0.4672 mL 1.1681 mL
30 mM 0.0389 mL 0.1947 mL 0.3894 mL 0.9734 mL
40 mM 0.0292 mL 0.1460 mL 0.2920 mL 0.7300 mL
50 mM 0.0234 mL 0.1168 mL 0.2336 mL 0.5840 mL
60 mM 0.0195 mL 0.0973 mL 0.1947 mL 0.4867 mL
80 mM 0.0146 mL 0.0730 mL 0.1460 mL 0.3650 mL
100 mM 0.0117 mL 0.0584 mL 0.1168 mL 0.2920 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

WKYMVm Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

WKYMVm187986-17-0WKYMVm-amide W-PeptideFormyl Peptide Receptor (FPR)PERKApoptosisProtein kinase R-like endoplasmic reticulum kinasePKR-like endoplasmic reticulum kinaseMicrogliaHUVECsSpinal cord injury modelHigh-fat fed mouse modelFormyl Peptide Receptor AgonistInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
WKYMVm
Cat. No.:
HY-P1120
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.